Pfizer revenues continue to depict lacklustre performances due to weak sales of its blockbuster drugs such as Lipitor and Viagra, amongst others. Pfizer's R&D;pipeline continues to appear weak, with 11 of its 25 drugs in Phase 3 comprising line extensions. The Wyeth acquisition was completed in October 2009 and Pfizer will start reporting performance from 4Q 09. Wyeth's pipeline is strong but requires significant R&D;investment from Pfizer....

LOE for Lipitor will subject the company to intense generic competition (e.g. Ranbaxy Laboratories Limited, India, will receive 180 days exclusivity to market a generic version of Lipitor) which is expected to significantly erode Lipitor’s revenues. We believe the acquisition of Wyeth Inc. (Wyeth) will partially offset the revenue loss over the medium term....